Trials / Unknown
UnknownNCT04558853
Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma
A Safety Study of CellProtect, an Autologous ex Vivo Expanded and Activated Natural Killer (NK) Cell Product, in Patients With Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multiple Myeloma (MM) is a lethal disease and at present no available treatment method seems to prevent the disease from progressing or relapsing in the long term. NK cells have a relatively high cytotoxic capacity and an anti tumour effect, suggesting a potential as a treatment of MM.This is a phase I, first-in-human, therapeutic exploratory study, where no benefits for the patients can be guaranteed. However, the theoretical implication is that the infused cells may have a positive antitumour effect for the participating individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | autologous NK cells | Autologous ex vivo expanded and activated NK cells |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
- First posted
- 2020-09-22
- Last updated
- 2021-02-17
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT04558853. Inclusion in this directory is not an endorsement.